Gallium (68Ga) gozetotide

DRUG2 trials

Sponsors

Point Biopharma Inc., Novartis Pharmaceuticals

Conditions

Metastatic castration-resistant prostate cancer (mCRPC)Prostate Cancer

Phase 1

Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

WithdrawnNCT06881823

Novartis PharmaceuticalsProstate Cancer

Start: 2026-06-29End: 2033-06-01Updated: 2025-12-29

Phase 3

SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment

Active, not recruitingCTIS2024-515604-39-00

Point Biopharma Inc.Metastatic castration-resistant prostate cancer (mCRPC)

Start: 2022-01-28Target: 65Updated: 2025-12-15